Please sign in so that we can notify you about a reply
Indications/Uses
For cerebral vascular accidents and cerebral insufficiencies; ischemic or even hemorrhagic acute accidents and chronic manifestations of the above accident of cerebral atherosclerosis; mental retardation in children; behavior and psychotic problems in old age.
Dosage/Direction for Use
Adults: The average dosage is 800 mg three times a day. When the desired effect has been obtained, gradually reduce to 400 mg three times a day. Or as prescribed by the physician.
Children: The daily dose depends on the weight of the child and the dose range is 40-50 mg/kg of body weight given in 3 separate doses. Once the desired result has been obtained, reduce the initial dose by half. Or as prescribed by the physician.
Children: The daily dose depends on the weight of the child and the dose range is 40-50 mg/kg of body weight given in 3 separate doses. Once the desired result has been obtained, reduce the initial dose by half. Or as prescribed by the physician.
Administration
May be taken with or without food.
Special Precautions
Caution should be exercised when Piracetam is administered in patients with renal insufficiency (creatinine clearance 60 mL/minute or serum creatinine 1.25 mg/100 mL).
Drug Interactions
Prothrombin time was increased in one patient stabilized on warfarin when treatment with Piracetam was started.
Storage
Store at temperatures not exceeding 30°C.
Action
Pharmacology: Piracetam is a nootropic agent, which improves directly the efficiency of the higher functions of the brain involved in cognitive processes such as those related to learning, memory though and consciousness, both in normal and deficient situations.
Piracetam modulates brain neurotransmission, promotes metabolic conditions for learning and memory retention.
Effects on cerebral neurotransmission: Piracetam increases synthesis of neurotransmitters in the brain.
Piracetam improves microcirculation by various rheological properties such as: enhanced red blood cell elasticity, reduced red blood adhesivity and aggregability, reduced platelet aggregation, enhanced phagocytosis and respiratory burst of neutrophils, prevention and inhibition of cerebral vasospasms.
Controlled studies in children presenting with developmental dyslexia have shown that Piracetam improves reading fluency and the capacity to comprehend the read matter.
Piracetam improves the ability to execute tasks after different brain aggressions such as hypoxia, intoxications, electroshock therapy.
Piracetam reduces the duration of a provoked vestibular nystagmus.
Piracetam improves cerebral flow and cerebral metabolic rates of oxygen and glucose in multi-dementia patients.
Piracetam improves the regional cerebral blood flow as well as the regional glucose consumption, without affecting blood flow and glucose consumption in the regions with normal perfusion, and inhibits hyperaggregability of activated platelets in patients presenting with acute cerebral ischemia.
Following oral dose, the peak plasma concentrations of Piracetam are achieved within 45 to 60 minutes. It is not metabolized and is excreted unchanged in urine. Half-life is 4 to 5 hours. Renal clearance of Piracetam is 80 mL/minute.
Piracetam modulates brain neurotransmission, promotes metabolic conditions for learning and memory retention.
Effects on cerebral neurotransmission: Piracetam increases synthesis of neurotransmitters in the brain.
Piracetam improves microcirculation by various rheological properties such as: enhanced red blood cell elasticity, reduced red blood adhesivity and aggregability, reduced platelet aggregation, enhanced phagocytosis and respiratory burst of neutrophils, prevention and inhibition of cerebral vasospasms.
Controlled studies in children presenting with developmental dyslexia have shown that Piracetam improves reading fluency and the capacity to comprehend the read matter.
Piracetam improves the ability to execute tasks after different brain aggressions such as hypoxia, intoxications, electroshock therapy.
Piracetam reduces the duration of a provoked vestibular nystagmus.
Piracetam improves cerebral flow and cerebral metabolic rates of oxygen and glucose in multi-dementia patients.
Piracetam improves the regional cerebral blood flow as well as the regional glucose consumption, without affecting blood flow and glucose consumption in the regions with normal perfusion, and inhibits hyperaggregability of activated platelets in patients presenting with acute cerebral ischemia.
Following oral dose, the peak plasma concentrations of Piracetam are achieved within 45 to 60 minutes. It is not metabolized and is excreted unchanged in urine. Half-life is 4 to 5 hours. Renal clearance of Piracetam is 80 mL/minute.
MedsGo Class
Nootropics & Neurotonics/Neurotrophics
Features
Brand
Normabrain-800
Full Details
Dosage Strength
800 mg
Drug Ingredients
- Piracetam
Drug Packaging
Film-Coated Tablet 1's
Generic Name
Piracetam
Dosage Form
Film-Coated Tablet
Registration Number
DRP-2764
Drug Classification
Prescription Drug (RX)